Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hematologic complications of immune checkpoint inhibitors
Michael H. Kroll, Cristhiam M. Rojas‐Hernandez, Cassian Yee
Blood (2021) Vol. 139, Iss. 25, pp. 3594-3604
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Iron overload disorders
Christine Hsu, Nizar H. Senussi, Kleber Yotsumoto Fertrin, et al.
Hepatology Communications (2022) Vol. 6, Iss. 8, pp. 1842-1854
Open Access | Times Cited: 86
Allosteric Regulation of IGF2BP1 as a Novel Strategy for the Activation of Tumor Immune Microenvironment
Yang Liu, Qiang Guo, Heng Yang, et al.
ACS Central Science (2022) Vol. 8, Iss. 8, pp. 1102-1115
Open Access | Times Cited: 85
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
Kai Rejeski, Ariel Perez Perez, Gloria Iacoboni, et al.
Science Advances (2023) Vol. 9, Iss. 38
Open Access | Times Cited: 32
Grade ≥ 3 hematologic adverse events of immunotherapy in advanced NSCLC patients: a systematic review and meta-analysis
Shuang Wang, Meng‐Ting Cai, Yajun Xiong, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access | Times Cited: 1
Diagnosis and Management of Adult Malignancy-Associated Hemophagocytic Lymphohistiocytosis
Jerry C. Lee, Aaron C. Logan
Cancers (2023) Vol. 15, Iss. 6, pp. 1839-1839
Open Access | Times Cited: 21
Radio-induced lymphopenia in the era of anti-cancer immunotherapy
François de Kermenguy, Lydia Meziani, Michele Mondini, et al.
International review of cell and molecular biology (2023), pp. 1-30
Closed Access | Times Cited: 18
COVID-19 and Anemia: What Do We Know So Far?
Luai Abu‐Ismail, Mohammad J. J. Taha, Mohammad T. Abuawwad, et al.
Hemoglobin (2023) Vol. 47, Iss. 3, pp. 122-129
Open Access | Times Cited: 13
Association of thrombocytopenia with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database
G. Liu, Shuxian Zhang, Zhuang Mo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Immune-checkpoint Inhibitors in Anti-cancer Armamentarium: a Double-edged Sword in Risk of Developing Autoimmunity and Immune-related Adverse Effects

Frontiers research topics (2025)
Closed Access
Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective Observational Study by Using the Common Data Model
Seok Jun Park, Seungwon Yang, Su-Hyun Lee, et al.
Diagnostics (2025) Vol. 15, Iss. 2, pp. 226-226
Open Access
Diagnosis and management of concurrent metastatic melanoma and chronic myelomonocytic leukemia
Kishan Bhatt, Anna Vaynrub, Jason Cham, et al.
Melanoma Research (2025)
Closed Access
Acquired amegakaryocytic thrombocytopaenia after treatment with immune checkpoint inhibitor as part of neoadjuvant treatment in a patient with bilateral breast cancer
Vivi Quoc Nguyen, Louise Kristensen, Henrik Frederiksen
BMJ Case Reports (2025) Vol. 18, Iss. 3, pp. e263434-e263434
Closed Access
Pembrolizumab associated immune thrombocytopenia
Perihan Perkin, Serhat Sekmek, Doğan Bayram, et al.
Journal of Chemotherapy (2025), pp. 1-5
Closed Access
Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003–2018
Joe West, Peter Stilwell, Hanhua Liu, et al.
HemaSphere (2022) Vol. 6, Iss. 11, pp. e797-e797
Open Access | Times Cited: 15
Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: A systematic review and network meta-analysis of phase 3 trials
Jingyi Hou, Ruiyang Xie, Zhuo Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
When inflammatory stressors dramatically change, disease phenotypes may transform between autoimmune hematopoietic failure and myeloid neoplasms
Xi-Chen Zhao, Bo Ju, Nuan-Nuan Xiu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Aplastic anemia secondary to adjuvant Osimertinib therapy: a case report and a review of literature
Ahmed Abdalhadi, Nabil E. Omar, Samah Kohla, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report
Tanja Fetter, Simon Fietz, Maya Bertlich, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Hemorrhage profile associated with immune checkpoint inhibitors: a systematic review and a real-world study based on the FAERS database
Mengting Chen, Zhichao He, Jianhong Zhu, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 4, pp. 497-511
Open Access | Times Cited: 2
Novel Cancer Therapeutics: Perioperative Implications and Challenges
Cristina Gutiérrez, Prabalini Rajendram, Olakunle Idowu
Anesthesia & Analgesia (2024)
Closed Access | Times Cited: 2
Immune Checkpoint Inhibitor-Related Cytopenias: About 68 Cases from the French Pharmacovigilance Database
M. Martin, Hoan-My Nguyen, C. Beuvon, et al.
Cancers (2022) Vol. 14, Iss. 20, pp. 5030-5030
Open Access | Times Cited: 9
Incidence and Risk of Hematological Adverse Events Associated With Immune Checkpoint Inhibitors: A Systematic Literature Review and Meta-Analysis
Takuma Ohashi, Kaoru Takase-Minegishi, Ayaka Maeda, et al.
Journal of Hematology (2023) Vol. 12, Iss. 2, pp. 66-74
Open Access | Times Cited: 5
Updates in toxicities associated with immune checkpoint inhibitors
Nina B. Curkovic, Douglas B. Johnson
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 9, pp. 1117-1129
Closed Access | Times Cited: 5
Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours
Naoya Maekawa, Satoru Konnai, Kenji Hosoya, et al.
PLoS ONE (2023) Vol. 18, Iss. 10, pp. e0291727-e0291727
Open Access | Times Cited: 5
Spatiotemporal evolution of AML immune microenvironment remodeling and RNF149-driven drug resistance through single-cell multidimensional analysis
Xin Wu, Zhongguang Wu, Woding Deng, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top